SLC5A2 and angina pectoris: Therefore, it seems that especially for patients with concomitant type 2 DM, treatment with SGLT-2 inhibitors may decrease the risk for subsequent AMI, while it might have no or minimal effect on the risk for other forms of CAD, mainly unstable angina.